Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Stock Forecast

OVID's stock price has decreased by -57.62% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 4 analysts that cover Ovid Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $3.13, which forecasts a 936.42% increase in the stock price over the next year. The lowest target is $1.5 and the highest is $4.

Price Target: $3.13 (+936.42%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$1.50	$3.13	$4.00	$4.00
Change	+396.69%	+936.42%	+1224.5%	+1224.5%

* Price targets were last updated on May 27, 2025.

Analyst Ratings

The average analyst rating for Ovid Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25	Jun '25
Strong Buy	3	3	3	3	3	2
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $2 → $1.5	Strong Buy	Maintains	$2 → $1.5	+396.69%	May 27, 2025
Thomas Shrader BTIG	BTIG	Strong Buy Maintains $5 → $4	Strong Buy	Maintains	$5 → $4	+1,224.50%	Mar 24, 2025
Laura Chico Wedbush	Wedbush	Buy Maintains $4 → $3	Buy	Maintains	$4 → $3	+893.38%	Mar 12, 2025
Francois Brisebois Oppenheimer	Oppenheimer	Hold → Buy Upgrades $4	Hold → Buy	Upgrades	$4	+1,224.50%	Jan 29, 2025
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $3	Strong Buy	Reiterates	$3	+893.38%	Dec 4, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

319.60K

Decreased by -43.53%

from 566.00K

Revenue Next Year

336.60K

Increased by 5.32%

from 319.60K

EPS This Year

-0.63

from -0.37

EPS Next Year

-0.67

from -0.63

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	12.62M	208.38M	1.50M	392.00K	566.00K	319.60K	336.60K	229.50K
Revenue Growth	-	1,551.57%	-99.28%	-73.91%	44.39%	-43.53%	5.32%	-31.82%
EPS	-1.39	1.76	-0.77	-0.73	-0.37	-0.63	-0.67	-0.91
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	9	8	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	598,500	735,000	577,500
Avg	319,597	336,600	229,500
Low	98,000	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	5.7%	130.0%	71.6%
Avg	-43.5%	5.3%	-31.8%
Low	-82.7%	-	-

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.55	-0.42	-0.83
Avg	-0.63	-0.67	-0.91
Low	-0.71	-0.74	-1.04

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.